EMEA-002077-PIP01-16-M01

Key facts

Invented name
Active substance
Fc- and CDR-modified humanised monoclonal antibody against C5
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0356/2017
PIP number
EMEA-002077-PIP01-16-M01
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of paroxysmal nocturnal haemoglobinuria
Route(s) of administration
Intravenous use
Contact for public enquiries
Alexion Europe SAS
Tel. +33 147100606
E-mail: pip.enquiries@alexion.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating